Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT00608985Phase 3Completed

Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Role: lead

NCT00606593Phase 2Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Role: lead

NCT01987739Phase 1Completed

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

Role: lead

NCT00640848Phase 1Completed

Almorexant in Primary Insomnia

Role: lead

All 4 trials loaded